Faculty Articles

Naltrexone/Bupropion ER (Contrave): Newly Approved Treatment Option for Chronic Weight Management in Obese Adults

Publication Title

P&T (Pharmacy & Therapeutics)

Volume

41

Issue

3

Publication Date / Copyright Date

3-1-2016

First Page

164

Last Page

172

Publisher

MediMedia

Abstract

Obesity is becoming an increasingly serious and costly health problem in the United States, with more than one-third of adults (34.9%) and 17% of children suffering from this condition.1 Obesity is defined as having a body mass index (BMI) greater than 30, while being overweight is defined as having a BMI between 25 and 29.9.2 Besides being a psychological burden on the patient, obesity is associated with increased risk of stroke, cardiovascular disease, type-2 diabetes, and the development of certain types of cancers, including esophageal, pancreatic, colon, and breast cancers.3,4 Obesity represents a huge burden to the U.S. health care system—$147 billion was spent on obesity in 2008 alone. Health care costs for obese patients were on average $1,429 higher than for patients of normal weight.5 The physiological, psychological, and financial effects associated with obesity have pushed health care professionals to come up with appropriate solutions to manage obesity and achieve better health outcomes.

Disciplines

Medicine and Health Sciences | Pharmacy and Pharmaceutical Sciences

Keywords

body mass index (BMI), Naltrexone/Bupropion ER (Contrave), obsesity, United States

Link to Full Text
Peer Reviewed

Find in your library

Share

 
COinS